Allison Shelley

May 30, 2015


CHICAGO — Mounting evidence supports the addition of docetaxel to standard hormone and radiation treatment in men with high-risk prostate cancer. This latest comes from a federally funded phase 3 clinical trial presented here at this year's American Society of Clinical Oncology meeting.

The 4-year overall survival rates were higher with docetaxel than standard therapy. The add-on chemotherapy was given for 18 weeks, starting a month after radiation.

"This finding could improve outcomes for thousands of men," lead investigator Howard Sandler, MD, from Cedars-Sinai Medical Center in Los Angeles, said in a statement issued in advance of the news conference on the study. "We also expect to see an even bigger survival advantage over time," he said.

This finding could improve outcomes for thousands of men.

The paradigm for years has been to treat prostate cancer with hormone therapy until there is no response, and then to try chemotherapy. But these results and those from the 3000-patient British STAMPEDE trial suggest that a more aggressive approach might be appropriate.

"Chemotherapy carries a modest increase in side effects," Dr. Sandler added, "so it is important that physicians discuss the balance of benefits and risks with their patients."

"If you accept the notion that docetaxel is better used early, how early should we use it?" asked David Graham, MD, from Levine Cancer Center in Charlotte, North Carolina, in Medscape Oncology's live blog.

"Do we add it in with PSA-only recurrence after primary therapy? Do we wait until nonmarker-only disease is present? All of these are questions that will require trials to answer," he explained.

Read the full news story here and further commentary here.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.